Strongyloides stercoralis seropositivity is not associated with increased symptoms in a remote Aboriginal community

Strongyloides stercoralis seropositivity is not associated with increased symptoms in a remote Aboriginal community Journal Article

Internal Medicine Journal

• Author(s): Hansen, Martin, Bowden, Emily, Currie, Bart J., Ward, Linda, Andrews, Ross M., Dhurrkay, Roslyn Gundjirryirr, Gurruwiwi, George Garambaka, Kearns, Therese
• Published: 2020
• Publisher: John Wiley & Sons, Ltd
• ISBN: 1444-0903

Link to resource Report broken link

Abstract: Background Strongyloides stercoralis is a soil-transmitted helminth, endemic in remote Aboriginal and Torres Strait Islander communities in northern Australia with estimates of prevalences up to 60%. Hyperinfection in the setting of immunosuppression is a rare but well-recognised cause of significant morbidity and mortality. However, the morbidity associated with chronic uncomplicated infection is less well characterised. Methods This retrospective case?control study measured the prevalence of symptoms potentially attributable to S. stercoralis infection and their association with seropositivity. Records of primary healthcare presentations were reviewed for symptoms in the 12 months before and after an ivermectin mass drug administration (MDA) in a remote Aboriginal community. Results One hundred and seventy-five S. stercoralis seropositive cases were matched with 175 seronegative controls. The most frequently reported symptom overall in the 12 months prior to the MDA was cough followed by abdominal pain, weight loss/malnutrition, diarrhoea and pruritis. Seropositive cases were not more likely than matched controls to have symptoms typically attributed to strongyloidiasis. In the seropositive cohort, we found no difference in symptoms in the 12 months before and after an ivermectin MDA despite a reduction in seroprevalence. Conclusion We found no evidence to suggest that S. stercoralis seropositivity was associated with increased symptoms when compared to matched seronegative controls. Treatment with ivermectin did not reduce symptoms in seropositive cases. Without evidence to support that population-based screening or treatment programs reduce symptoms, the emphasis must remain on identifying and managing those few individuals with immunosuppression that predisposes them to potentially life-threatening hyperinfection. This article is protected by copyright. All rights reserved.

• Urls: https://doi.org/10.1111/imj.14884
• Keywords: Strongyloides, Epidemiology, Rural Health, Neglected Diseases, Mass Drug Administration